

Douglas L Boggs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11667208/publications.pdf>

Version: 2024-02-01

22
papers

1,885
citations

471061

17
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

2410
citing authors

#	ARTICLE	IF	CITATIONS
1	The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. <i>Psychopharmacology</i> , 2018, 235, 1923-1932.	1.5	162
2	Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. <i>Schizophrenia Research</i> , 2018, 194, 62-69.	1.1	26
3	Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ^9 -Tetrahydrocannabinol. <i>Neuropsychopharmacology</i> , 2018, 43, 142-154.	2.8	178
4	The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ^9 -THC) in humans. <i>Journal of Psychopharmacology</i> , 2018, 32, 1308-1318.	2.0	27
5	Psychoactive Substance Use by Adults With Schizophrenia Before and During Cannabis Withdrawal. <i>primary care companion for CNS disorders, The</i> , 2016, 18, .	0.2	2
6	Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia. <i>Current Pharmaceutical Design</i> , 2014, 20, 5077-5092.	0.9	25
7	Cannabis withdrawal in chronic cannabis users with schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 240-245.	1.5	20
8	Pilot study of Intravenous Nicotine Effects on Cognitive Performance in Schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 323-324.	1.1	4
9	Treatment of Hyperprolactinemia and Gynecomastia With Adjunctive Aripiprazole in 2 Men Receiving Long-Acting Injectable Antipsychotics. <i>primary care companion for CNS disorders, The</i> , 2013, 15, .	0.2	4
10	Diagnostic criteria for cannabis withdrawal syndrome. <i>Drug and Alcohol Dependence</i> , 2012, 123, 141-147.	1.6	96
11	Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial. <i>Schizophrenia Research</i> , 2012, 134, 207-210.	1.1	47
12	Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 86-91.	0.7	53
13	Cigarette Smoking and Mortality Risk in People With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 832-838.	2.3	130
14	The role of antihistaminic effects in the misuse of quetiapine: A case report and review of the literature. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 555-558.	2.9	29
15	The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. <i>Schizophrenia Bulletin</i> , 2010, 36, 71-93.	2.3	822
16	Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. <i>Drug and Alcohol Dependence</i> , 2010, 111, 120-127.	1.6	134
17	The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia. <i>Clinical Neuropharmacology</i> , 2009, 32, 69-74.	0.2	30
18	Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice. <i>Psychiatric Quarterly</i> , 2008, 79, 111-119.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Quetiapine at high doses for the treatment of refractory schizophrenia. <i>Schizophrenia Research</i> , 2008, 101, 347-348.	1.1	21
20	Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia. <i>Schizophrenia Research</i> , 2008, 103, 161-168.	1.1	32
21	Feasibility of Reducing the Duration of Placebo-Controlled Trials in Schizophrenia Research. <i>Schizophrenia Bulletin</i> , 2008, 34, 292-301.	2.3	26
22	Reaching for Wellness in Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2007, 30, 453-479.	0.7	16